Quidel (QDEL) versus InVivo Therapeutics (NVIV) Critical Survey

InVivo Therapeutics (NASDAQ: NVIV) and Quidel (NASDAQ:QDEL) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, earnings, valuation, institutional ownership, risk, profitability and analyst recommendations.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for InVivo Therapeutics and Quidel, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
InVivo Therapeutics 0 1 0 0 2.00
Quidel 0 0 6 1 3.14

InVivo Therapeutics presently has a consensus price target of $6.00, suggesting a potential upside of 1,098.80%. Quidel has a consensus price target of $58.50, suggesting a potential upside of 11.01%. Given InVivo Therapeutics’ higher possible upside, equities research analysts clearly believe InVivo Therapeutics is more favorable than Quidel.

Volatility & Risk

InVivo Therapeutics has a beta of 2.46, meaning that its stock price is 146% more volatile than the S&P 500. Comparatively, Quidel has a beta of 0.89, meaning that its stock price is 11% less volatile than the S&P 500.

Institutional & Insider Ownership

10.4% of InVivo Therapeutics shares are held by institutional investors. Comparatively, 93.3% of Quidel shares are held by institutional investors. 3.9% of InVivo Therapeutics shares are held by company insiders. Comparatively, 22.0% of Quidel shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares InVivo Therapeutics and Quidel’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
InVivo Therapeutics N/A N/A -$26.74 million ($0.74) -0.68
Quidel $277.74 million 6.61 -$8.16 million ($0.07) -752.86

Quidel has higher revenue and earnings than InVivo Therapeutics. Quidel is trading at a lower price-to-earnings ratio than InVivo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares InVivo Therapeutics and Quidel’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
InVivo Therapeutics N/A -158.99% -125.62%
Quidel -2.94% -3.02% -1.23%

Summary

Quidel beats InVivo Therapeutics on 10 of the 14 factors compared between the two stocks.

About InVivo Therapeutics

InVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, focus on developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries (SCI). It is developing Neuro-Spinal Scaffold implant, an investigational bioresorbable polymer scaffold for acute SCI; and Therapeutic Trails injection program for the treatment of chronic SCI. The company was founded in 2005 and is headquartered in Cambridge, Massachusetts.

About Quidel

Quidel Corporation is engaged in the development, manufacturing and marketing of diagnostic testing solutions. These diagnostic testing solutions are separated into four product categories: immunoassays, molecular assays, virology and specialty products. The Company sells its products directly to end users and distributors, in each case, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, universities, retail clinics, pharmacies and wellness screening centers. Its diagnostic solutions aid in the detection and diagnosis of critical diseases and other medical conditions, including infectious diseases, women’s health, gastrointestinal diseases, autoimmune diseases, bone health and thyroid diseases. The Company provides diagnostic testing solutions under various brand names, including Quidel, QuickVue, QuickVue+, MicroVue, FreshCells, D3 FastPoint, Super E-Mix, ELVIS, Sofia, Quidel Molecular, Amplivue, Lyra and Thyretain.

Receive News & Ratings for InVivo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InVivo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Tampa Bay Starting Relievers In Place of Starters
Tampa Bay Starting Relievers In Place of Starters
Teen Juan Soto Hits Home Run in First At-Bat
Teen Juan Soto Hits Home Run in First At-Bat
Ji-Man Choi Receives Another Chance in Milwaukee
Ji-Man Choi Receives Another Chance in Milwaukee
Marlins vs Dodgers sets a 10-year record in MGM sportsbooks
Marlins vs Dodgers sets a 10-year record in MGM sportsbooks
Strikeouts Once Again Plaguing Cubs
Strikeouts Once Again Plaguing Cubs
Atlanta Braves: A Mix of Young and Old
Atlanta Braves: A Mix of Young and Old


Leave a Reply

 
© 2006-2018 BBNS.